Innocell / PhotonPharma - LARVOL DELTA

CIP2023-001: Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy in Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: PhotonPharma, Inc. | Trial completion date: Jun 2026 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Jun 2026

Trial completion date • Trial primary completion date • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor

CIP2023-001: Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy in Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: PhotonPharma, Inc. | Trial completion date: Dec 2025 ➔ Jun 2026 | Initiation date: Jan 2025 ➔ Jun 2025 | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial completion date • Trial initiation date • Trial primary completion date • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • MUC16

CIP2023-001: Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy in Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: PhotonPharma, Inc. | Trial completion date: Mar 2025 ➔ Dec 2025 | Initiation date: Jun 2024 ➔ Jan 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025

Trial completion date • Trial initiation date • Trial primary completion date • Oncology • Ovarian Cancer • Solid Tumor • MUC16

PhotonPharma Secures $2.5 Million in Seed Funding to Advance Clinical Trial for Ovarian Cancer Treatment (PRNewswire) - "PhotonPharma...is pleased to announce the successful closing of a $2.5 million seed financing round. This vital funding will support the Phase I clinical trial of Innocell, an innovative therapy for the treatment of advanced ovarian cancer."

Financing • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy in Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: PhotonPharma, Inc.

New P1 trial • Oncology • Ovarian Cancer • Solid Tumor • MUC16

PhotonPharma, Inc. Receives FDA Clearance for a First in Human Clinical Study for Stage III/IV Ovarian Cancer Treatment with the Investigational Autologous Vaccine Therapy, Innocell (PRNewswire) - "PhotonPharma...announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with its Phase I clinical study for the treatment of Stage III/IV ovarian cancer using Innocell, its investigational groundbreaking autologous cell-based vaccine therapy. This therapeutic approach employs inactivated tumor cells, prepared by a proprietary process based on UV light and riboflavin, after isolation of the cells from a patient's tumor....The Phase 1 clinical trial for Innocell will evaluate its safety, tolerability, and potential immune response indicators in patients with Stage III/IV ovarian cancer. PhotonPharma anticipates initiating patient enrollment in the near future, with the aim of profiling the therapeutic potential of this innovative autologous vaccine therapy."

IND • New P1 trial • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor